{
    "clinical_study": {
        "@rank": "162945", 
        "arm_group": {
            "arm_group_label": "Vitamin D3", 
            "arm_group_type": "Experimental", 
            "description": "Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days."
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study of oral vitamin D supplementation to determine if patients with\n      Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum\n      25-hydroxyvitamin D levels.  The investigators will also assess whether the immunologic or\n      relevant gene expression response to oral vitamin D supplementation differs in patients with\n      MS and healthy controls."
        }, 
        "brief_title": "Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Sclerosis, Relapsing-remitting", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  Healthy or multiple sclerosis\n\n          -  Aged 18 to 60\n\n          -  Body mass index is between 18 kg/m2 and 30 kg/m2\n\n          -  Screening 25-hydroxyvitamin D level \u2264 75 nmol/L (30 ng/mL)\n\n          -  White race\n\n          -  Non-Hispanic ethnicity\n\n          -  Willing to use birth control during study\n\n          -  Willing to not use tanning bed during study\n\n        If subject has multiple sclerosis:\n\n          -  Relapsing-remitting MS, as defined by McDonald 2005 criteria\n\n          -  Screening Expanded Disability Status Scale score \u2264 3.0\n\n          -  Using no medication for MS, or taking Copaxone, (glatiramer acetate), interferons, or\n             natalizumab\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing\n\n          -  Taking multivitamin & unwilling to remain off it during study\n\n          -  Taking cod liver oil & unwilling to remain off it during study\n\n          -  On a fat-restricted diet\n\n          -  History of renal disease or nephrolithiasis (kidney stones)\n\n          -  History of liver disease\n\n          -  Taking thiazide diuretics\n\n          -  History of hyperthyroidism\n\n          -  History of infection with Mycobacterium species\n\n          -  History of sarcoidosis\n\n          -  History of cancer\n\n          -  History of cardiac disease\n\n          -  History of HIV\n\n          -  History of gastrointestinal disorder\n\n          -  Taking medications that interfere with gastrointestinal absorption\n\n          -  Cigarette smoker in past month\n\n          -  Use of illicit drugs in past month\n\n          -  Use of steroids in past month\n\n          -  History of hypercalcemia, and screening serum calcium \u2264 10 mg/dL (UCSF) or \u2264 10.7\n             mg/dL (Johns Hopkins)\n\n          -  History of hypercalciuria\n\n          -  Evidence of anemia (Hgb <11.0 g/dL)\n\n          -  History of other serious medical conditions\n\n          -  Taking medications that involve the P450 system or may interact with vitamin D\n             (digoxin, diltiazem, verapamil, cimetidine, heparin, or low-molecular weight heparin)\n\n          -  Other concerns about safety from the perspective of the treating physician\n\n        If subject has MS:\n\n        -History of major heat sensitivity (leading to sun-avoidant behaviors)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667796", 
            "org_study_id": "JH067055"
        }, 
        "intervention": {
            "arm_group_label": "Vitamin D3", 
            "intervention_name": "Vitamin D3", 
            "intervention_type": "Dietary Supplement"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple sclerosis", 
            "Healthy controls", 
            "Pharmacokinetics", 
            "Vitamin D"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California, San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls", 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Ellen M Mowry, MD, MCR", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in mean serum level of 25-hydroxyvitamin D", 
            "safety_issue": "No", 
            "time_frame": "90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667796"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Ellen M. Mowry", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cytokine levels and percentages of T and B cells", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "measure": "Gene expression microarray", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }
        ], 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}